(Total Views: 445)
Posted On: 05/07/2025 10:56:47 AM
Post# of 154725
Gilead paid $21B for a single indication, and early data suggests LL offers much better results for that indication.
One indication. CRC early trial data also likely available to suitors under NDA.
So someone can buy CYDY for the same (or more) and get all the potential of all the other indications thrown in at no extra charge.
Every time I have a weak moment I think of $21B for Trodelvy.
Minor nerve calmer.
Nothing's guaranteed, but the biz case is there for all to see, if only under NDA.
One indication. CRC early trial data also likely available to suitors under NDA.
So someone can buy CYDY for the same (or more) and get all the potential of all the other indications thrown in at no extra charge.
Every time I have a weak moment I think of $21B for Trodelvy.
Minor nerve calmer.
Nothing's guaranteed, but the biz case is there for all to see, if only under NDA.
(11)
(0)
